The Cystic Fibrosis Foundation is investing up to $9 million in additional funds in Arcturus Therapeutics to test ARCT-032, an inhaled messenger RNA therapeutic candidate that could treat the underlying cause of cystic fibrosis in all people living with the disease.
The medication now is approved for use in children with cystic fibrosis ages 1 month to less than 4 months old who have at least one mutation in their cystic fibrosis transmembrane conductance regulator gene.
Enrollment has begun in an early-stage clinical trial evaluating phage therapy (bacteriophage) in adults with cystic fibrosis who carry Pseudomonas aeruginosa in their lungs.
A study, published in the Journal of Cystic Fibrosis, looks at early markers of cystic fibrosis.
Read More
The combined use of patient-reported symptom data and objective lung function measures may help manage acute respiratory events in pediatric CF patients.
Read More
Using a model reproducing a respiratory epithelium, teams from the University of Geneva have discovered that a film of liquid is sufficient to restore the airways’ seal and lower the risk of bacterial infection.
Read More
The Ohio Cobra Club, a nonprofit organization of car enthusiasts in Ohio, will raffle off a replica Shelby 427 Cobra with proceeds donated to the Cystic Fibrosis Foundation.
Read More
Spirovant Sciences says its new research facilities in Philadelphia will allow the company to accelerate development of its lead program targeting cystic fibrosis.
Read More
Published monthly, the journal CHEST features peer-reviewed, original research in chest medicine: Pulmonary, critical care and sleep medicine and related disciplines.
Read More
Sionna Therapeutics is developing first-in-class small molecules designed to restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
Read More
Compared with isotonic saline, inhaled hypertonic saline resulted in positive lung changes in children with cystic fibrosis, research published in Lancet found.
Read More
The Cystic Fibrosis Foundation announced its first-ever Golden Ticket Competition to find the next promising treatment for cystic fibrosis in a collaboration with Bakar Labs, the incubator at the University of California, Berkeley’s Bakar BioEnginuity Hub.
Read More
Researchers investigated how BMI corresponds with recovery after lung transplants in CF patients.
Read More
A resistance-exercise training program can improve muscle strength in children with cystic fibrosis who have mild to moderate pulmonary impairment, a study recently published in Respiratory Medicine found.
Read More
The Cystic Fibrosis Foundation announced $1.6 million in awards for eight research grants focused on early detection and diagnosis of chronic lung allograft dysfunction.
Read More